Updates are available Correction dated 2025-02-19
Click to view Correction: https://doi.org/10.1038/s41586-025-08776-8
-
Authors
Gribonika, Inta https://orcid.org/0000-0002-5694-1315
Band, Victor I.
Chi, Liang
Perez-Chaparro, Paula Juliana
Link, Verena M. https://orcid.org/0000-0002-3207-312X
Ansaldo, Eduard https://orcid.org/0000-0002-7128-3373
Oguz, Cihan https://orcid.org/0000-0002-2860-3546
Bousbaine, Djenet https://orcid.org/0000-0003-2683-9544
Fischbach, Michael A. https://orcid.org/0000-0003-3079-8247
Belkaid, Yasmine https://orcid.org/0000-0001-9962-3571
- License Information
-
More Information
Article History
Received: 10 December 2023
Accepted: 8 November 2024
First Online: 11 December 2024
Change Date: 19 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-08776-8
Competing interests
: M.A.F. is a co-founder of Kelonia and Revolution Medicines, a member of the scientific advisory boards of the Chan Zuckerberg Initiative, NGM Biopharmaceuticals and TCG Labs–Soleil Labs, and an innovation partner at The Column Group. D.B., Y.B. and M.A.F. are inventors on patent applications submitted by Stanford University and the Chan Zuckerberg Biohub that cover methods for using engineered bacteria to elicit antigen-specific immune cells.
